NEW GLOBAL RESEARCH: FOUR NEW, IMPROVED DRUG REGIMENS COULD CUT TREATMENT TIME FOR DRUG RESISTANT TUBERCULOSIS BY UP TO TWO-THIRDS
The Union World Conference on Lung Health 2023 - Wednesday 15 November press release
“RUNNING OUT OF EXCUSES”: TB LEADER CONDEMNS INACTION IN ERADICATING TB AS UNION WORLD CONFERENCE BEGINS
The Union World Conference on Lung Health 2023 - Wednesday 15 November opening press release
Experts identify clinical standards for adverse effects to TB treatment
A panel of 65 global experts have identified eight clinical standards for the management of adverse effects during treatment for tuberculosis (TB).
Assessing TB-related comorbidities, risks and disability in China
A new study in China has found that it was possible and valuable to assess people with tuberculosis (TB) for symptoms, comorbidities, risk factors and disability at the start and end of TB treatment.
Risk of TB nine times higher in prisons globally
For the first time ever researchers, sponsored by The Union, have estimated the rate of tuberculosis (TB) in incarcerated persons, having analysed data from almost every country in the world (193 out of 195 countries) between 2000 and 2019.
Challenges of ending drug-resistant tuberculosis (DRTB) the focus of Special Edition of the International Journal of Tuberculosis and Lung Disease (IJTLD)
Drug-resistant TB (DRTB) continues to be a public health threat and is one of the leading antimicrobial resistant infections globally. Worldwide in 2019, close to half a million people developed DRTB. However, only 38 per cent of people with DRTB started treatments and of those treated, only 57 per cent were treated successfully.